DEA Updates Synthetic Dissociative Scheduling: Diphenidine in Schedule I
The DEA synthetic dissociative scheduling update places diphenidine in Schedule I due to its high abuse potential and lack of accepted medical use. This reflects regulatory efforts to control emerging novel psychoactive substances. Clinicians should…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products to Schedule III
The DEA rescheduling cannabis products from Schedule I to Schedule III marks a pivotal regulatory change. This shift applies to FDA-approved cannabis-derived medications, easing prescribing and research barriers. Clinicians should note this change…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA synthetic ketamine schedule I placement of 2-fluorodeschloroketamine reflects urgent regulatory action on novel psychoactive substances. This temporary scheduling addresses abuse potential and lack of accepted medical use. Clinicians should stay…
Diphenidine Scheduling Update Under DEA Controlled Substances Act
The diphenidine DEA scheduling update marks a significant regulatory action under the Controlled Substances Act. This update highlights the evolving policy landscape for synthetic dissociative drugs. Understanding this scheduling update is critical for…
Policy Watch: DEA Scheduling Actions on Synthetic Drugs — June 18, 2026
This update covers DEA scheduling synthetic drugs 2026 with six key regulatory actions impacting clinical research and cannabis-related therapies. The DEA placed several novel synthetic substances into Schedule I, affecting legal status and research…